Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world with its medicines, and is developing a pipeline of innovative medicines.
The company focuses its research in three therapeutic areas: inflammation, oncology, and general medicine. Medicines typically address diseases for which there are limited treatment options or provide a viable alternative to those treatments that are otherwise available. Amgen is also a leader in developing and manufacturing biosimilars, which have the potential to offer more affordable, life-altering treatment options.
Amgen aims to help employees at every level build and strengthen skills required to meet the evolving needs of the business, as well as advance into new roles. The company’s online learning hub is accessible to all staff globally and includes resources for skills development, manager effectiveness, and time management.
Within the U.S., Canada, and Puerto Rico, Amgen offers a program that reimburses participating staff members for college tuition, books, and specified exam and registration fees. Amgen also offers a training curriculum to prepare new managers to lead and inspire their teams.
To inspire the next generation of innovators, in 2021 the Amgen Foundation supports science education programs that reached over 27 million students and educators worldwide, and it provided some $3 million to support racial and social justice initiatives, economic empowerment, and equal opportunity in education.
In 2021, Amgen committed to achieving net zero carbon emissions in operations by 2027, along with a 40% reduction in water use and a 75% reduction in waste disposed.
Through the RISE (Representation in Clinical Research) Initiative, Amgen continued working toward increasing the ethnic and racial diversity of participants in clinical trials of investigational medicines.
To expand access to treatments, some $2.2 billion of medicines were provided at no cost to uninsured or underinsured patients in the United States through the Amgen Safety Net Foundation, and Amgen provided 900,000 daily doses of medicines at no cost in more than 20 low- and middle-income countries through our partnership with Direct Relief.